IAC/Interactivecorp vs BIO-TECHNE Corp — how do they compare? IAC/Interactivecorp trades at $40.94 (market cap $3.05B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: BIO-TECHNE Corp is far larger — about 3.7× IAC/Interactivecorp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while IAC/Interactivecorp pays none. Which is the better fit depends on your goals — on Pluang, investors hold IAC/Interactivecorp for 79 Days and BIO-TECHNE Corp for 63 Days on average.
| PPLI | TECH | |
|---|---|---|
Market Cap | $3.05B | $11.36B |
Volume | 931,019 | 5,390,331 |
Sector | Media | Health |
52-Week High | $47.62 | $72.61 |
52-Week Low | $31.52 | $43.31 |
Typical Hold Time | 79 Days | 63 Days |
Enterprise Value | $3.53B | $11.39B |
Dividend Yield | — | 0.44% |
Signals from Pluang's Aura AI — not financial advice
PPLI trades at $40.59, down 1.7% in the past 24 hours, with a bullish technical signal from moving averages. The stock shows mixed fundamentals: revenue declined to $2.39B in 2025 with a net loss of $104.03M, but valuation ratios appear attractive with a P/E of 6.87 and P/B of 0.59. Recent news highlights potential M&A activity, as MGM Resorts is reportedly considering a bid for PPLI, following PPLI's withdrawal of its own offer to buy MGM.
The outlook is cautiously optimistic, supported by strong analyst consensus (71.4% buy ratings) and potential upside from strategic deals. Key risks include inconsistent profitability, high debt levels, and execution challenges in a competitive media landscape. Earnings volatility remains a concern, but the low valuation and M&A speculation provide catalysts for investor interest.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Trailing returns across standard periods
Latest headlines on both assets
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →